Group 1 - The core stock price of David Medical as of July 31, 2025, closed at 14.21 yuan, down 3.00% from the previous trading day, with a trading volume of 370 million yuan [1] - The stock experienced significant volatility during the day, with a high of 14.98 yuan and a low of 14.21 yuan, resulting in a fluctuation of 5.26% [1] - David Medical specializes in the research, production, and sales of medical devices, primarily focusing on neonatal medical equipment such as incubators and radiant warmers [1] Group 2 - On July 31, the stock showed rapid fluctuations, with a rebound of over 2% within 5 minutes in the morning session, followed by a quick decline of over 2% within the next 5 minutes, indicating active market trading [1] - The net outflow of main funds was 9.0994 million yuan, accounting for 0.45% of the circulating market value, suggesting market divergence regarding the short-term outlook of the stock [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of David Medical, indicating a significant decline in revenue and profit compared to the previous year [1][2] - As of July 28, David Medical's stock closed at 14.48 yuan, with a 6.55% increase, and a rolling PE ratio of 99.95, marking a new low in 198 days, with a total market capitalization of 4.17 billion yuan [1] - The company operates in the medical device industry, focusing on obstetric and pediatric care equipment, minimally invasive surgical instruments, and emergency ICU products [1] Group 2 - For the first quarter of 2025, David Medical reported a revenue of 121 million yuan, a year-on-year decrease of 22.00%, and a net profit of 22.57 million yuan, down 40.78% [2] - The company's sales gross margin stands at 57.13% [2] - In terms of industry comparison, the average PE ratio for the medical device sector is 55.28, while the median is 38.06, placing David Medical at the 104th position in the industry ranking [1][2]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of David Medical, indicating a significant decline in revenue and profit in the latest quarterly report [1][2] - As of July 24, David Medical's stock closed at 13.3 yuan, with a PE ratio of 91.80, marking a new low in 88 days, and a total market capitalization of 3.83 billion yuan [1] - The average PE ratio for the medical device industry is 54.55, with a median of 37.54, positioning David Medical at 104th place in the industry ranking [1][2] Group 2 - For Q1 2025, David Medical reported a revenue of 121 million yuan, reflecting a year-on-year decrease of 22.00%, and a net profit of 22.57 million yuan, down 40.78% year-on-year [2] - The company's gross profit margin stands at 57.13%, indicating its ability to maintain profitability despite declining revenues [2] - David Medical specializes in obstetric and pediatric care equipment, minimally invasive surgical instruments, and emergency ICU products, with a range of key products including incubators and neonatal monitoring devices [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of David Medical, indicating a decline in revenue and profit, alongside a high PE ratio compared to industry averages [1][2] - As of July 16, David Medical's stock closed at 12.96 yuan, with a PE ratio of 89.46, marking a new low in 80 days, and a total market capitalization of 3.732 billion yuan [1] - The company experienced a net outflow of 7.8469 million yuan in principal funds on July 16, with a total outflow of 18.6796 million yuan over the past five days [1] Group 2 - In the latest quarterly report for Q1 2025, David Medical reported an operating income of 121 million yuan, a year-on-year decrease of 22.00%, and a net profit of 22.5677 million yuan, down 40.78% [2] - The company's gross profit margin stands at 57.13% [2] - David Medical operates in the medical device sector, focusing on obstetric and pediatric care equipment, minimally invasive surgical instruments, and emergency ICU products [1]

Company Overview - David Medical's closing price on July 4 was 12.77 yuan, down 1.01%, with a rolling PE ratio of 88.15 times and a total market value of 3.678 billion yuan [1] - The company ranks 105th in the medical device industry, which has an average PE ratio of 51.05 times and a median of 36.62 times [1] Financial Performance - For Q1 2025, the company reported revenue of 121 million yuan, a year-on-year decrease of 22.00%, and a net profit of 22.57 million yuan, down 40.78% year-on-year [2] - The sales gross margin was reported at 57.13% [2] Shareholding Structure - As of the Q1 2025 report, there are 2 institutional investors holding shares in David Medical, including 1 QFII and 1 insurance company, with a total holding of 1.2529 million shares valued at 1.5 million yuan [1] Product Portfolio - David Medical specializes in obstetric and pediatric care equipment, minimally invasive surgical instruments, and emergency ICU products, including incubators, radiant warmers, jaundice treatment devices, and various monitoring and therapeutic equipment [1] Industry Recognition - The company has been recognized as a "Manufacturing Industry Single Champion Cultivation Enterprise" by the Ministry of Industry and Information Technology and has received multiple honors, including "Famous Brand in Zhejiang Province" and "AAA Credit Rating Enterprise" [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of David Medical, indicating a significant decline in revenue and profit in the latest quarter [1][2] - As of June 30, David Medical's stock closed at 12.7 yuan, with a PE ratio of 87.66, which is significantly higher than the industry average of 50.61 [1][2] - The company has a total market capitalization of 36.58 billion yuan, ranking 105th in the medical device industry based on PE ratio [1][2] Group 2 - In the first quarter of 2025, David Medical reported an operating income of 1.21 billion yuan, a year-on-year decrease of 22.00%, and a net profit of 22.57 million yuan, down 40.78% [2] - The company's sales gross margin stands at 57.13%, indicating a relatively high profitability despite the decline in revenue and profit [2] - David Medical specializes in obstetric and pediatric care equipment, minimally invasive surgical instruments, and emergency ICU products, with key products including incubators and neonatal monitoring devices [1]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of David Medical, indicating a significant decline in revenue and profit in the first quarter of 2025 compared to the previous year [1][2] - As of June 5, 2023, David Medical's stock closed at 12.62 yuan, down 1.48%, with a rolling price-to-earnings (PE) ratio of 87.11 times, and a total market capitalization of 3.635 billion yuan [1] - The company operates in the medical device industry, specifically focusing on obstetric and pediatric care equipment, minimally invasive surgical instruments, and emergency ICU products [1] Group 2 - In the first quarter of 2025, David Medical reported operating revenue of 121 million yuan, a year-on-year decrease of 22.00%, and a net profit of 22.57 million yuan, down 40.78% year-on-year, with a gross profit margin of 57.13% [2] - The average PE ratio for the medical device industry is 50.97 times, with a median of 36.67 times, positioning David Medical at the 102nd rank within the industry [2] - The company has received multiple honors, including recognition as a "Manufacturing Industry Single Champion Cultivation Enterprise" by the Ministry of Industry and Information Technology, and various accolades in Zhejiang Province for its credit management and specialized innovation [1]

Core Viewpoint - David Medical's stock closed at 12.4 yuan, down 2.52%, with a rolling PE ratio of 85.59 times, and a total market value of 3.571 billion yuan [1] Company Summary - David Medical specializes in obstetric and pediatric care equipment, minimally invasive surgical instruments, and emergency ICU products, with key products including incubators, radiant warmers, jaundice treatment devices, EEG monitors, and more [1] - As of Q1 2025, two institutions held shares in David Medical, with a total of 1.2529 million shares valued at 0.015 billion yuan [1] - The company has received multiple honors, including recognition as a "Manufacturing Industry Single Champion Cultivation Enterprise" and "AAA Credit Rating Enterprise" [1] Industry Summary - The average PE ratio for the medical device industry is 49.46 times, with a median of 36.16 times, placing David Medical at 102nd in the industry ranking [2] - The company's Q1 2025 performance showed a revenue of 121 million yuan, a year-on-year decrease of 22.00%, and a net profit of 22.5677 million yuan, down 40.78%, with a gross margin of 57.13% [2]

Group 1 - The core viewpoint of the articles highlights the financial performance and market position of David Medical, indicating a decline in revenue and profit while maintaining a high PE ratio compared to industry averages [1][2] - As of May 7, David Medical's stock closed at 12.16 yuan, with a PE ratio of 83.93, which is significantly higher than the industry average of 49.02 and the median of 36.25 [1][2] - The company has a total market capitalization of 3.502 billion yuan, ranking 101st in the medical device industry based on PE ratio [1][2] Group 2 - In the first quarter of 2025, David Medical reported a revenue of 121 million yuan, representing a year-on-year decrease of 22.00%, and a net profit of 22.57 million yuan, down 40.78% from the previous year [2] - The company's gross profit margin stands at 57.13%, indicating a relatively strong profitability despite the decline in revenue and net profit [2] - David Medical specializes in obstetric and pediatric care equipment, minimally invasive surgical instruments, and emergency ICU products, with a range of key products including incubators and neonatal monitoring devices [1]

4月1日，戴维医疗今日收盘12.77元，上涨3.40%，滚动市盈率PE（当前股价与前四季度每股收益总和的 比值）达到41.73倍，总市值36.78亿元。 最新一期业绩显示，2024年三季报，公司实现营业收入4.03亿元，同比-12.21%；净利润6330.79万元， 同比-48.44%，销售毛利率56.78%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)81戴维医疗41.7324.923.1336.78亿行业平均 46.4650.224.93109.40亿行业中值33.0731.042.5248.44亿1硕世生物-1956.94-1956.941.2340.43亿2诺唯 赞-583.67-583.672.5299.23亿3博晖创新-305.50-188.093.3746.89亿4康泰医学-294.1934.523.0157.22亿5华 大基因-216.51236.822.24220.01亿6奥精医疗-121.42-121.421.5522.00亿7睿昂基因-83.80-83.801.3012.12亿 8热景生物-57.27-57.273.15102.65亿9华大智造-54.80-54.804.11 ...